Bortezomib Added to Daunorubicin and Cytarabine during Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients with Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years

JIANG  Bin; LIAO  Peng-jun

doi:10.3969/j.issn.1671-5144.2013.05.004

JIANG Bin, LIAO Peng-jun. Bortezomib Added to Daunorubicin and Cytarabine during Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients with Previously Untreated Acute Myeloid Leukemia Age 60 to 75 YearsJ. Journal of Evidence-Based Medicine, 2013, 13(5): 268-270. DOI: 10.3969/j.issn.1671-5144.2013.05.004

Citation:

Bortezomib Added to Daunorubicin and Cytarabine during Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients with Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years

No content published by the Journal of Evidence-Based Medicine may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journal without permission.

All articles published represent the opinions of the authors, and do not reflect the official policy of the Journal of Evidence-Based Medicine’ Sponsors or the Editorial Board, unless this is clearly specified.

Abstract

FullText(HTML)

References (0)

Cited By

Turn off MathJax

Article Contents

Bortezomib Added to Daunorubicin and Cytarabine during Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients with Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years

Catalog

Export File

Citation

Format

Content